{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":7,"podcast":3,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06337318\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06337318","nct_id":"NCT06337318","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06337318. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive rituximab IV on day 1 of cycle 1 and receive rituximab and hyaluronidase SC on days 8, 15 and 22 of cycle 1 and SC on day 1 of subsequent cycles. Cycles repeat every 56 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.","label":"Arm I (Rituximab, rituximab and hyaluronidase)","type":"EXPERIMENTAL"},{"description":"Patients receive mosunetuzumab SC on days 1, 8 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and/or PET/CT and blood sample collection on study and during follow up.","label":"Arm II (Mosunetuzumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-03-31","type":"ESTIMATED"},"conditions":["Classic Follicular Lymphoma","Follicular Lymphoma With Unusual Cytological Features"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Mosunetuzumab","type":"BIOLOGICAL"},{"name":"Positron Emission Tomography","type":"PROCEDURE"},{"name":"Rituximab","type":"BIOLOGICAL"},{"name":"Rituximab and Hyaluronidase Human","type":"BIOLOGICAL"}],"last_update":"2026-10-09","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"3-year milestone progression free survival (PFS)","timeFrame":"From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 3 years"},{"measure":"PFS","timeFrame":"From date of registration to date of first observation of progressive disease, transformation to diffuse large B cell lymphoma, or death due to any cause, up to 10 years"}],"references":[],"start_date":{"date":"2024-10-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT06337318"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06337318"}